Page 252 - Binder2

• Proactive management of chronic disease where
continuity of care is limited
• Biologic literacy and empowerment in emerging
biotech regions

It's not just about making drugs more available.
It’s about reclaiming agency over the tools of healing.

Global Health, Re-Engineered

The WHO has repeatedly emphasized the need for
affordable, scalable, immune-compatible therapies—
especially for noncommunicable diseases that are now
rising in low- and middle-income countries.

Edible biologics answer that call. Not as a philanthropic
gesture, but as a systemic redesign.

They offer:

• Lower total cost of care
• Simplified logistics
• Improved adherence
• Reduced immune rejection
• Fewer hospital touchpoints

And most importantly: a way to close the gap between
what’s scientifically possible and what’s globally
achievable.

Because the true measure of a medical breakthrough isn’t
how it performs in Boston or Basel.

250